---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-138931"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:12:32.776086+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q1 cash burn $84.1M; resmetirom NDA on track for Q2 2023 with Breakthrough Therapy

## Summary
- Cash and securities $329.5M at March 31, 2023, down from $358.8M at Dec 31, 2022.
- Operating expenses $78.3M for Q1 2023, up from $57.6M in Q1 2022; R&D $62.2M, G&A $16.2M.
- Resmetirom NDA for NASH with fibrosis remains on track for Q2 2023; FDA Breakthrough Therapy designation received.
- MAESTRO-NASH trial enrollment complete; primary results to be presented at EASL in June 2023.
- Interest income rose to $3.8M from $0.1M; interest expense $2.3M from loan facility.

## SEC filing metadata
- accession: 0001193125-23-138931
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/0001193125-23-138931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/d398921d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-138931
- JSON: https://secwatch.observer/filing/0001193125-23-138931.json
- Plain text: https://secwatch.observer/filing/0001193125-23-138931.txt

## Key facts
- Earnings Releases
  MADRIGAL PHARMACEUTICALS, INC. reported financial results for first quarter 2023.
  - Period: first quarter 2023
  - Result: reported results
  source text: On May 9, 2023, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/0001193125-23-138931-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.